Transforming growth factor beta-2 (TGF-β2)

Transforming growth factor beta‑2 (TGF‑β2) is a secreted glycosylated cytokine belonging to the transforming growth factor beta superfamily. It plays essential roles during embryonic development—including heart formation—and regulates diverse cellular processes such as proliferation, migration, differentiation, angiogenesis, immune response modulation, and extracellular matrix production. Like other family members (TGF‑β1/3), it is synthesized as a precursor that undergoes proteolytic processing to yield an active dimeric ligand. The mature form signals through specific serine/threonine kinase receptors on the cell surface; this activates intracellular Smad proteins that regulate gene transcription. Dysregulation of TGF‑β2 signaling has been implicated in various pathologies including cancer progression/metastasis; cardiovascular malformations; fibrotic diseases; ocular conditions like glaucoma; autoimmune disorders; and abnormal wound healing. Therapeutically targeting TGF‑β2 poses challenges due to its pleiotropic functions but remains an area of interest for antibody-based drugs such as lerdelimumab. Its expression levels can serve as biomarkers for disease activity or prognosis in select contexts.

Other names

Glioblastoma-derived T-cell suppressor factorG-TSFBSC-1 cell growth inhibitorPolyerginCetermin

Antagonism or neutralization by monoclonal antibodies to block ligand-receptor interaction and downstream signaling cascade via Smad proteins or related pathways